Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion for Chronic Kidney Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mayo Clinic Florida, Jacksonville, FLChronic Kidney Disease+4 MoreAllogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion - Drug
Eligibility
30 - 80
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test if it is safe to give people with chronic kidney disease mesenchymal stem cells, which may help treat the disease.

Eligible Conditions
  • Chronic Kidney Disease
  • Diabetic Kidney Disease
  • Diabetes
  • Type 2 Diabetes
  • Type 1 Diabetes

Treatment Effectiveness

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 22 months

22 months
Adverse events and/or serious adverse events

Trial Safety

Trial Design

2 Treatment Groups

Dose Arm 2
1 of 2
Dose Arm 1
1 of 2

Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion · No Placebo Group · Phase 1

Dose Arm 2
Drug
Experimental Group · 1 Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion · Intervention Types: Drug
Dose Arm 1
Drug
Experimental Group · 1 Intervention: Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 22 months

Who is running the clinical trial?

LaTonya J. HicksonLead Sponsor
1 Previous Clinical Trials
20 Total Patients Enrolled
LaTonya Hickson, MDPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
30 Total Patients Enrolled

Eligibility Criteria

Age 30 - 80 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many participants have been recruited for this trial?

"Yes, the current data posted on clinicaltrials.gov confirms that this medical study is actively recruiting participants. This research was first launched on October 7th 2021 and last updated November 9th 2022. The trial necessitates 40 patients from two different sites to be enrolled in order for it to successfully conclude." - Anonymous Online Contributor

Unverified Answer

Are there any vacancies for study participants still available?

"Affirmative. According to the clinicaltrials.gov information, this medical study is currently gathering participants with first posting date of October 7th 2021 and last update on November 9th 2022. 40 patients need to be recruited from two distinct locations." - Anonymous Online Contributor

Unverified Answer

Is the target population of this research project limited to individuals over 25 years of age?

"This trial is accepting participants aged between 30 and 80 years." - Anonymous Online Contributor

Unverified Answer

Has the FDA sanctioned a single-dose approach utilizing allogeneic adipose-derived mesenchymal stem cells?

"We deem the safety of Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion to be a 1 due to being in Phase 1; there is minimal evidence that its safe and effective." - Anonymous Online Contributor

Unverified Answer

Is it possible to become part of this experiment?

"Candidates hoping to be admitted into this research project must meet two requirements - they have a diagnosis of diabetes mellitus, type 2 and their age is between 30-80. Currently, the trial desires around 40 participants in total." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.